NIPH Clinical Trials Search

A Phase 2 study of Docetaxel and Bevacizumab as the second line treatment for patients with non-squamous non-small cell lung cancer previously treated with platinum-based chemotherapy.

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	non-squamous non-small cell lung cancer
Date of first enrollment	2011/11/01
Target sample size	41
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Docetaxel+Bevacizumab

Outcome(s)

Primary Outcome	Response Rate
Secondary Outcome	Safety, Progression Free Survival

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1. No prior treatment with Docetaxel and Bevacizumab 2.History of hemoptysis with 2.5mL per time or more. 3.Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 4.massive pleural or pericardial effusion. 5. CNS metastasis 6. Patients with a concomitant or prior invasive malignancy who have had any evidence of the disease within the last 5 years 7. Patients with severe complications Unstable angina. cardiovascular disease, severe heart disease, heart failure within 3month. Uncontrollable diabetes mellitus and hypertension Active infection 8. In pregnancy, during breast feeding, or possibility of pregnancy. 9.The past history of severe allergic reactions 10. psychiatric patients 11. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.